This column was originally published on RealMoney on July 7 at 11:19 a.m. EDT. It's being republished as a bonus for TheStreet.com readers.Now we are seeing reasons why the drug stocks are gaining traction. It makes sense: weakness in the economy. Obviously, the tug of war is between Big Pharma and Big Biotech. To me, the biotechs have the edge because of the lack of a generic-drug threat. The ones that have the most momentum have to be Celgene ( CELG) and Genentech ( DNA). They have new drugs, drugs that are costing a lot to the consumer and drugs that are all patent protected. I also like Gilead ( GILD) because of its terrific anti-AIDS cocktail that could gain some serious use as word spreads of its viability. Of the Big Pharma, I favor GlaxoSmithKline ( GSK) because of that mix of generic and proprietary products; but I am also amazed at the continual strength in Merck ( MRK), which is good news because it strengthens the possibility for Merck to be making acquisitions again. Bottom line: This group is back because of the employment numbers and because of the disappointments of the 3Ms and the AMDs. Random musings: Watch this SEC split on options. It will lessen the possibilities of serious sanctions against anyone who is accused of spring-loading options because enforcement staff would rather spend time making slamdunks than on questionable cases involving options.